Helicobacter pylori eradication: kill the bug and save the pill?
Jeffries
M A
MA
Department of Internal Medicine, Consortium for Health Outcomes, University of Michigan Medical Center, Ann Arbor, USA.
Scheiman
J M
JM
Fendrick
A M
AM
D000863:Antacids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D012307:Risk Factors; D016037:Single-Blind Method; D013752:Tetracycline / Q000627:therapeutic use
D000863:Antacids; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D008795:Metronidazole; D009288:Naproxen; D013752:Tetracycline; D001729:Bismuth